Addressing unmet medical needs in disorders of the complement and coagulation systems

Harnessing the catalytic power of proteases

Protease engineering platform – Late-stage asset in Phase 3, robust complement portfolio, clinical-stage hemophilia assets, and differentiated protease medicines

The Protease Medicines Company

Learn more about our Pipeline

Hemophilia A or B w Inhibitors – ToB
Phase 3
FVIID/Glanzmann/Hemlibra – ToB
Phase 1/2
C3 degrader for Dry AMD
Preclinical
Enhanced CFI
Preclinical
 
Preclinical
 
Preclinical
Hemophilia B FIX Gene Therapy
Preclinical

Protease Engineering Platform

 

Complement

CB 2782-PEG

IVT Anti-C3 Dry AMD

CB 4332 SQ Enhanced CFI

SQ Systemic Complement Degraders

The Catalyst Advantage

Drug candidates for severe medical conditions

Learn more about the medicines we are developing

See our pipeline

Addressing diseases with unmet medical needs

Share our passion about treating disease

See our publications 

Experienced and passionate team

Learn more about the Catalyst team and mission/culture

Meet the team